ArticleOpen medicine (Warsaw, Poland)2026
Computational design of a multiepitope vaccine targeting VP1 and VP2 capsid proteins of simian virus 40 (SV40) for enhanced immune activation.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Designing a multi-epitope vaccine against yellow fever virus using immunoinformatics approaches.Open medicine (Warsaw, Poland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to design and evaluate a computationally constructed multiepitope vaccine targeting Simian Virus 40 (SV40) by predicting and selecting immunogenic B-cell and T-cell epitopes derived from the VP1 and VP2 capsid proteins using bioinformatics approaches. Methods: B and T-cell epitopes from VP1 and VP2 were predicted and screened for antigenicity, non-allergenicity, and non-toxicity. Structural modeling and validation were performed using PSIPRED, trRosetta, and a Ramachandran plot. Population coverage was assessed using the IEDB. Molecular docking with TLR3 and TLR5, immune simulations, Results: Molecular docking with human receptors TLR3 and TLR5, revealing strong binding affinities of -1,008.3 kcal/mol and -1,309.2, and further validated using MD simulation analysis. The Conclusions: The designed vaccine demonstrated high immunogenic potential; further
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.